pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

25,707 catalysts · 6,102 approval · 5,000 device 510k · 4,728 grant · 3,086 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 57 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2022-04-05×clear all
type
  • approval6,102
  • device 510k5,000
  • grant4,728
  • 8k filing3,086
  • device pma2,000
  • device recall2,000
recall
1,126
  • device adverse event1,000
  • earnings583
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of May 2, 2022

    18
    ›May 3, 2022approval1562d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalIGC Pharma, Inc.

    Sponsor: ALKEM LABS LTD. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›May 3, 2022approval1562d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalIGC Pharma, Inc.

    Sponsor: PHARMOBEDIENT. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›May 3, 2022approval1562d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: ETHYPHARM. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›May 3, 2022approval1562d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalIGC Pharma, Inc.

    Sponsor: RHODES PHARMS. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›May 3, 2022approval1562d agoSUBOXONE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: INDIVIOR. Form: FILM. Route: BUCCAL, SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›May 3, 2022approval1562d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalIGC Pharma, Inc.

    Sponsor: BARR. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›May 3, 2022approval1562d agoZUBSOLV (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalEdenbridge Pharmaceuticals LLC

    Sponsor: EDENBRIDGE PHARMS. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›May 3, 2022approval1562d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: SPECGX LLC. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›May 3, 2022approval1562d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: LANNETT CO INC. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›May 3, 2022approval1562d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›May 3, 2022approval1562d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: ACTAVIS ELIZABETH. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›May 3, 2022approval1562d agoVOQUEZNA TRIPLE PAK (AMOXICILLIN) — FDA approvalamoxicillin + clarithromycin + vonoprazan

    Sponsor: PHATHOM. Form: CAPSULE, TABLET, TABLET. Route: ORAL

    full page →amoxicillin + clarithromycin + vonoprazan →fda approvals ↗
    ›May 3, 2022approval1562d agoVOQUEZNA DUAL PAK (AMOXICILLIN) — FDA approvalamoxicillin + vonoprazan fumarate

    Sponsor: PHATHOM. Form: CAPSULE, TABLET. Route: ORAL

    full page →amoxicillin + vonoprazan fumarate →fda approvals ↗
    ›May 4, 2022approval1561d agoPOMALIDOMIDE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA PHARMS USA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›May 4, 2022approval1561d agoENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approvaltrastuzumab deruxtecan

    Sponsor: DAIICHI SANKYO. Form: INJECTABLE. Route: INJECTION

    full page →trastuzumab deruxtecan →fda approvals ↗
    ›May 4, 2022approval1561d agoENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approvaltrastuzumab deruxtecan

    Sponsor: DAIICHI SANKYO. Form: INJECTABLE. Route: INJECTION

    full page →trastuzumab deruxtecan →fda approvals ↗
    ›May 4, 2022approval1561d agoTAMSULOSIN HYDROCHLORIDE — FDA approvalTAMSULOSIN HYDROCHLORIDE

    Sponsor: ASCENT PHARMS INC. Form: CAPSULE. Route: ORAL

    full page →TAMSULOSIN HYDROCHLORIDE →fda approvals ↗
    ›May 6, 2022approval1559d agoDOXIL (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE) — FDA approvalDoxil

    Sponsor: BAXTER HLTHCARE CORP. Form: INJECTABLE, LIPOSOMAL. Route: INJECTION

    full page →Doxil →fda approvals ↗

    Week of May 9, 2022

    10
    ›May 9, 2022approval1556d agoVORICONAZOLE — FDA approvalVORICONAZOLE

    Sponsor: MEITHEAL. Form: POWDER. Route: INTRAVENOUS

    full page →VORICONAZOLE →fda approvals ↗
    ›May 10, 2022approval

    Week of May 16, 2022

    11
    ›May 16, 2022approval1549d agoESTRADIOL AND PROGESTERONE (ESTRADIOL) — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›May 18, 2022approval

    Week of May 23, 2022

    11
    ›May 24, 2022approval1541d agoMETHADONE HYDROCHLORIDE — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: MYLAN INSTITUTIONAL. Form: INJECTABLE. Route: INJECTION

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›May 25, 2022approval
    ← prev
    page 2 of 515
    next →
    1555d ago
    VIGABATRIN — FDA approvalVIGABATRIN

    Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL

    full page →VIGABATRIN →fda approvals ↗
    ›May 10, 2022approval1555d agoMAGNESIUM SULFATE — FDA approvalMAGNESIUM SULFATE

    Sponsor: BAXTER HLTHCARE CORP. Form: INJECTABLE. Route: INJECTION

    full page →MAGNESIUM SULFATE →fda approvals ↗
    ›May 11, 2022approval1554d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›May 11, 2022approval1554d agoIMFINZI (DURVALUMAB) — FDA approvalASTRAZENECA PLC

    Sponsor: ASTRAZENECA UK LTD. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›May 11, 2022approval1554d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

    Sponsor: PHARMACYCLICS LLC. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›May 11, 2022approval1554d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

    Sponsor: PHARMACYCLICS LLC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›May 13, 2022approval1552d agoMOUNJARO (TIRZEPATIDE) — FDA approvalZEPBOUND

    Sponsor: ELI LILLY AND CO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →ZEPBOUND →fda approvals ↗
    ›May 13, 2022approval1552d agoNIZORAL ANTI-DANDRUFF (KETOCONAZOLE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: KRAMER. Form: SHAMPOO. Route: TOPICAL

    full page →fda approvals ↗
    ›May 13, 2022approval1552d agoDIAMOX (ACETAZOLAMIDE) — FDA approvalAccord Healthcare Inc

    Sponsor: TEVA BRANDED PHARM. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    1547d ago
    PANTOPRAZOLE SODIUM — FDA approvalPANTOPRAZOLE SODIUM

    Sponsor: ASPIRO. Form: INJECTABLE. Route: INTRAVENOUS

    full page →PANTOPRAZOLE SODIUM →fda approvals ↗
    ›May 19, 2022approval1546d agoEBANGA (ANSUVIMAB-ZYKL) — FDA approvalansuvimab

    Sponsor: RIDGEBACK BIOTHERAPEUTICS. Form: POWDER. Route: IV (INFUSION)

    full page →ansuvimab →fda approvals ↗
    ›May 19, 2022approval1546d agoNEOSTIGMINE METHYLSULFATE — FDA approvalNEOSTIGMINE METHYLSULFATE

    Sponsor: AMPHASTAR PHARMS INC. Form: SOLUTION. Route: INTRAVENOUS

    full page →NEOSTIGMINE METHYLSULFATE →fda approvals ↗
    ›May 19, 2022approval1546d agoAMBRISENTAN — FDA approvalAMBRISENTAN

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →AMBRISENTAN →fda approvals ↗
    ›May 20, 2022approval1545d agoDUPIXENT (DUPILUMAB) — FDA approvaldupilumab

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION

    full page →dupilumab →fda approvals ↗
    ›May 20, 2022approval1545d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›May 20, 2022approval1545d agoTYVASO (TREPROSTINIL) — FDA approvalUNITED THERAPEUTICS Corp

    Sponsor: UNITED THERAP. Form: SOLUTION. Route: INHALATION

    full page →fda approvals ↗
    ›May 20, 2022approval1545d agoCLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER (CLINDAMYCIN PHOSPHATE) — FDA approvalCLEOCIN

    Sponsor: PFIZER. Form: INJECTABLE. Route: INJECTION

    full page →CLEOCIN →fda approvals ↗
    ›May 20, 2022approval1545d agoCLEOCIN HYDROCHLORIDE (CLINDAMYCIN HYDROCHLORIDE) — FDA approvalclindamycin hydrochloride

    Sponsor: PFIZER. Form: CAPSULE. Route: ORAL

    full page →clindamycin hydrochloride →fda approvals ↗
    ›May 20, 2022approval1545d agoCLEOCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — FDA approvalCLEOCIN

    Sponsor: PFIZER. Form: INJECTABLE. Route: INJECTION

    full page →CLEOCIN →fda approvals ↗
    1540d ago
    TIZANIDINE HYDROCHLORIDE — FDA approvalTIZANIDINE HYDROCHLORIDE

    Sponsor: APOTEX INC. Form: CAPSULE. Route: ORAL

    full page →TIZANIDINE HYDROCHLORIDE →fda approvals ↗
    ›May 25, 2022approval1540d agoTIZANIDINE HYDROCHLORIDE — FDA approvalZydus Therapeutics Inc

    Sponsor: ZYDUS PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›May 25, 2022approval1540d agoPEMETREXED DISODIUM — FDA approvalLilly USA LLC

    Sponsor: RELIANCE LIFE. Form: POWDER. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›May 26, 2022approval1539d agoPEMETREXED DISODIUM — FDA approvalAlimta

    Sponsor: SANDOZ. Form: SOLUTION. Route: INTRAVENOUS

    full page →Alimta →fda approvals ↗
    ›May 27, 2022approval1538d agoMEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalSpexotras

    Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

    full page →Spexotras →fda approvals ↗
    ›May 27, 2022approval1538d agoTAFINLAR (DABRAFENIB MESYLATE) — FDA approvaldabrafenib mesylate ODT

    Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL

    full page →dabrafenib mesylate ODT →fda approvals ↗
    ›May 27, 2022approval1538d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›May 27, 2022approval1538d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›May 27, 2022approval1538d agoEVRYSDI (RISDIPLAM) — FDA approvalEVRYSDI

    Sponsor: GENENTECH INC. Form: FOR SOLUTION. Route: ORAL

    full page →EVRYSDI →fda approvals ↗
    ›May 27, 2022approval1538d agoEVRYSDI (RISDIPLAM) — FDA approvalEVRYSDI

    Sponsor: GENENTECH INC. Form: FOR SOLUTION. Route: ORAL

    full page →EVRYSDI →fda approvals ↗
    $IGC0.2670+0.41%
    $IGC0.2670+0.41%
    $PHAT8.6500+0.93%
    $INDV39.20+1.90%
    $IGC0.2670+0.41%
    $PHAT8.6500+0.93%
    $AMRX17.47-2.29%
    $IGC0.2670+0.41%
    $AMRX17.47-2.29%
    $AZN159.50-1.49%
    $BMY63.75-1.68%
    $ABBV249.50+0.61%
    $LLY1223.99-0.64%
    $AMPH20.14-0.81%
    $UTHR525.28-0.83%
    $REGN802.21-0.72%
    $ABBV249.50+0.61%
    $PFE26.63-1.57%
    $PFE26.63-1.57%
    $NVS155.21-1.01%
    $PFE26.63-1.57%
    $BMY63.75-1.68%
    $BMY63.75-1.68%
    $NVS155.21-1.01%